Cerevel: Drop On Data Delay For EMPOWER Program Provides Buy Opportunity

Terry Chrisomalis
Investing Group Leader

Summary

  • Cerevel Therapeutics Holdings, Inc. experienced a drop in shares due to a delay in releasing top-line results from studies on emraclidine for schizophrenia treatment.
  • Emraclidine is also being developed for Alzheimer's Disease Psychosis, with a phase 1 study already initiated.
  • The company has a well-capitalized financial position and multiple upcoming data readouts for other drugs in its pipeline.
  • Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More »

Macro science background,macro science experiment background,Laboratory research, dropping liquid to test tube. Test tube containing chemical liquid in laboratory, lab chemistry or science research and development concept.

banjongseal324/iStock via Getty Images

Cerevel Therapeutics Holdings, Inc. (CERE) has an extensive pipeline, however, shares of the company dropped after it reported that there would be a delay for the release of top line results from a few of

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis
13.46K Followers

Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.

He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

More on CERE

Trending Analysis

Trending News